Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-AAZTA-093 PET/CT in Prostate Cancer
NCT06437496Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Diagnostic imaging agent
- Countries
- 1
01
Overview
Phase 1, open-label trial of [68Ga]Ga-AZ-093 in prostate cancer (PCa) (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Safety evaluation at 7 days. Started Apr 2024; status: recruiting.
02
Drugs
[68Ga]Ga-AZ-093
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06437496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437496.